NCT05060588

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

The Effect of Sacubitril/Valsartan Versus Valsartan on the Short-term Prognosis of Hypertensive Patients With Acute Myocardial Infarction

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Qingdao Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Studies have demonstrated that the early initiation of ACEI/ARB to patients with acute myocardial infarction is beneficial, especially in patients combined with reduced LVEF or mild-moderate heart failure. Therefore, ACEI/ARB is a traditional treatment for patients post-infarction. Recent clinical trials have demonstrated that Sacubitril/Valsartan is more beneficial than Ramipril to patients post-PCI.Besides, Sacubitril/Valsartan is also effective for essential hypertension.This study aims to assess the effect of Sacubitril/Valsartan on short-term prognosis in hypertensive patients with acute myocardial infarction compared against Valsartan.

Conditions

• Myocardial Infarction
• Hypertension

Interventions

Type	Name	Description
DRUG	Sacubitril/Valsartan 49/51mg/Tab	patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
DRUG	Valsartan 80mg/Tab	Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.

Timeline

• Start date: 2021-10-01
• Primary completion: 2022-10-01
• Completion: 2023-02-01
• First posted: 2021-09-29
• Last updated: 2021-09-29

Locations

1 site across 1 country: China